Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
03 nov. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Completes Enrollment of the First Patient Cohort for its Intermediate-Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
02 nov. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Starts Enrollment of the First Patient Cohort in its Intermediate Size Patient Population Expanded Access Program to Evaluate Foralumab in Non-Active Secondary Multiple Sclerosis Patients
26 oct. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
19 oct. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery,...
Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer's Disease Patients
12 oct. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
29 sept. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
28 sept. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit“Effect of nasal...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
23 sept. 2022 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
21 sept. 2022 07h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
20 sept. 2022 06h34 HE
|
Tiziana Life Sciences Ltd.
The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and enduranceThe patient showed clinically significant improvement in the Expanded Disability...